A direct effect of infliximab on the expression of the tight junction proteins in the colitis model was provided by a study by (Xiao et al., 2022) showing that administration of infliximab significantly improved the level of occludin but did not affect ZO-1 expression in DSS-induced colitis model. The gene discussed is TJP1; the disease is colitis.